期刊
CHEST
卷 137, 期 6, 页码 1432-1435出版社
AMER COLL CHEST PHYSICIANS
DOI: 10.1378/chest.09-2576
关键词
-
资金
- American Thoracic Society
- Sarcoidosis Research Foundation
- National Institutes of Health NIH
The treatment options for patients with sarcoidosis are presently limited, and it is unclear which treatments are most effective for any given patient. We have identified a sarcoidosis phenotype characterized by CD4(+) lymphopenia and resistance to conventional immunosuppressants, such as corticosteroids and methotrexate. Based on recent reports linking tumor necrosis factor (TNF)-alpha to regulatory T-cell (Treg) dysfunction, we hypothesized that sarcoidosis-associated CD4(+) lymphopenia would resolve with anti-TNF alpha treatment. Five consecutive patients with CD4(+) lymphopenia were treated with a chimeric anti-TNF alpha antibody (infliximab). Clinical disease manifestations and peripheral blood T-cell subsets were assessed before and after infliximab treatment. All patients experienced significant increases in absolute peripheral blood lymphocyte and CD4(+) T-cell counts and demonstrated improvement in clinical disease manifestations in response to infliximab. No change in the distribution of T-cell subsets was noted. The presence of CD4(+) lymphopenia identifies a distinct sarcoidosis phenotype that is particularly responsive to anti-TNF alpha therapy. CHEST 2010; 137(6):1432-1435
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据